{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T16:05:01Z","timestamp":1780329901353,"version":"3.54.1"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,14]],"date-time":"2026-04-14T00:00:00Z","timestamp":1776124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.msard.2026.107199","type":"journal-article","created":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:44:10Z","timestamp":1776120250000},"page":"107199","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Prescriptions and healthcare use in multiple sclerosis patients within general practices in the Netherlands"],"prefix":"10.1016","volume":"110","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6853-2714","authenticated-orcid":false,"given":"Cynthia M.C.","family":"Lemmens","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joost W.","family":"Vanhommerig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart J.","family":"Knottnerus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jop P.","family":"Mostert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joep","family":"Killestein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigit A.","family":"de Jong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2026.107199_bib0002","doi-asserted-by":"crossref","first-page":"592","DOI":"10.3390\/pharmaceutics14030592","article-title":"Prevalence and severity of potential drug\u2013drug interactions in patients with multiple sclerosis with and without polypharmacy","volume":"14","author":"Bachmann","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.msard.2026.107199_bib0003","doi-asserted-by":"crossref","first-page":"140","DOI":"10.7224\/1537-2073.2022-046","article-title":"Epidemiological insights on medication concurrency and polypharmacy in people with multiple sclerosis in Greece","volume":"25","author":"Bakirtzis","year":"2023","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2026.107199_bib0004","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12165379","article-title":"Depression and anxiety in association with polypharmacy in patients with multiple sclerosis","volume":"12","author":"Baldt","year":"2023","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.msard.2026.107199_bib0005","article-title":"Barriers to clinical follow-up visits in multiple sclerosis: a nationwide register-based study","volume":"10","author":"Beczek","year":"2024","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107199_bib0006","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J. R. Stat. Soc. Ser. B"},{"key":"10.1016\/j.msard.2026.107199_bib0007","doi-asserted-by":"crossref","first-page":"97","DOI":"10.7326\/0003-4819-155-2-201107190-00005","article-title":"Low health literacy and health outcomes: an updated systematic review","volume":"155","author":"Berkman","year":"2011","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.msard.2026.107199_bib0008","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2023.1330066","article-title":"Polypharmacy in patients with multiple sclerosis and the impact on levels of care and therapy units","volume":"14","author":"Br\u00fcggemann","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.msard.2026.107199_bib0009","doi-asserted-by":"crossref","first-page":"207","DOI":"10.7224\/1537-2073.2014-076","article-title":"Medications are associated with falls in people with multiple sclerosis: a prospective cohort study","volume":"17","author":"Cameron","year":"2015","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2026.107199_bib0010","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s11910-023-01289-9","article-title":"Polypharmacy in Multiple sclerosis: prevalence, risks, and mitigation strategies","volume":"23","author":"Chapman","year":"2023","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.msard.2026.107199_bib0011","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson","year":"1987","journal-title":"J. Chronic Dis."},{"key":"10.1016\/j.msard.2026.107199_bib0012","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1177\/13524585221122207","article-title":"Polypharmacy and multiple sclerosis: a population-based study","volume":"29","author":"Chertcoff","year":"2023","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107199_bib0013","article-title":"The socioeconomic impact of disability progression in multiple sclerosis: a retrospective cohort study of the German NeuroTransData (NTD) registry","volume":"9","author":"Dillon","year":"2023","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107199_bib0014","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1093\/fampra\/13.5.439","article-title":"Multiple sclerosis: management in Dutch general practice","volume":"13","author":"Donker","year":"1996","journal-title":"Fam. Pract."},{"key":"10.1016\/j.msard.2026.107199_bib0017","doi-asserted-by":"crossref","DOI":"10.1186\/s13293-019-0243-9","article-title":"Polypharmacy in patients with multiple sclerosis: a gender-specific analysis","volume":"10","author":"Frahm","year":"2019","journal-title":"Biol. Sex Differ."},{"key":"10.1016\/j.msard.2026.107199_bib0018","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0211120","article-title":"Polypharmacy in outpatients with relapsing-remitting multiple sclerosis: a single-center study","volume":"14","author":"Frahm","year":"2019","journal-title":"PLoS One"},{"key":"10.1016\/j.msard.2026.107199_bib0015","article-title":"The risk of polypharmacy, comorbidities and drug-drug interactions in women of childbearing age with multiple sclerosis. Ther","volume":"13","author":"Frahm","year":"2020","journal-title":"Adv. Neurol. Disord."},{"key":"10.1016\/j.msard.2026.107199_bib0016","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1080\/14740338.2020.1720646","article-title":"Polypharmacy among patients with multiple sclerosis: a qualitative systematic review","volume":"19","author":"Frahm","year":"2020","journal-title":"Expert Opin. Drug Saf."},{"key":"10.1016\/j.msard.2026.107199_bib0019","article-title":"Disease-modifying drugs, multiple sclerosis and infection-related healthcare use in British Columbia, Canada: a population-based study","volume":"29","author":"Graf","year":"2024","journal-title":"Lancet Reg. Heal. Am."},{"key":"10.1016\/j.msard.2026.107199_bib0022","doi-asserted-by":"crossref","first-page":"81","DOI":"10.7224\/1537-2073.2023-014","article-title":"Investigating the impact of polypharmacy and anticholinergic medication burden on objective cognitive performance in adults with multiple sclerosis","volume":"26","author":"Huebner","year":"2024","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2026.107199_bib0020","doi-asserted-by":"crossref","first-page":"91","DOI":"10.7224\/1537-2073.2021-062","article-title":"Characteristics of prescription drug use among individuals with multiple sclerosis in the US Medicare population","volume":"24","author":"Hartung","year":"2022","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2026.107199_bib0023","doi-asserted-by":"crossref","first-page":"14","DOI":"10.7224\/1537-2073.2013-040","article-title":"Lower urinary tract symptom prevalence and management among patients with multiple sclerosis","volume":"17","author":"Khalaf","year":"2015","journal-title":"Int. J. MS Care"},{"key":"10.1016\/j.msard.2026.107199_bib0024","doi-asserted-by":"crossref","DOI":"10.1177\/2042098620933741","article-title":"An overview of prevalence, determinants and health outcomes of polypharmacy","volume":"11","author":"Khezrian","year":"2020","journal-title":"Ther. Adv. Drug Saf."},{"key":"10.1016\/j.msard.2026.107199_bib0025","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/S1474-4422(22)00426-4","article-title":"Family planning considerations in people with multiple sclerosis","volume":"22","author":"Krysko","year":"2023","journal-title":"Lancet. Neurol."},{"key":"10.1016\/j.msard.2026.107199_bib0026","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2024.106207","article-title":"Prevalence and incidence of multiple sclerosis in the Netherlands","volume":"93","author":"Lemmens","year":"2025","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107199_bib0027","doi-asserted-by":"crossref","DOI":"10.1002\/pds.70070","article-title":"Antibiotic utilization among people with Multiple sclerosis in the Netherlands, 2018-2020","volume":"33","author":"Leung","year":"2024","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"10.1016\/j.msard.2026.107199_bib0028","first-page":"e3","article-title":"Health literacy association with health behaviors and health care utilization in multiple sclerosis: a cross-sectional study. Interact","volume":"3","author":"Marrie","year":"2014","journal-title":"J. Med. Res."},{"key":"10.1016\/j.msard.2026.107199_bib0029","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","article-title":"What is polypharmacy? a systematic review of definitions","volume":"17","author":"Masnoon","year":"2017","journal-title":"BMC Geriatr."},{"key":"10.1016\/j.msard.2026.107199_bib0030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000488799","article-title":"Comorbidities are associated with altered health services use in Multiple sclerosis: a prospective cohort study","volume":"51","author":"McKay","year":"2018","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.msard.2026.107199_bib0031","doi-asserted-by":"crossref","DOI":"10.1177\/13524585241251986","article-title":"Trends in central nervous system-active polypharmacy among people with multiple sclerosis","volume":"30","author":"Naizer","year":"2024","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107199_bib0021","unstructured":"National Health Care Institute (2023) Home. Available at: https:\/\/english.zorginstituutnederland.nl\/ (Accessed: 19 March 2025)."},{"key":"10.1016\/j.msard.2026.107199_bib0032","doi-asserted-by":"crossref","DOI":"10.1186\/s12883-019-1582-1","article-title":"The prevalence of lower urinary tract symptoms based on individual and clinical parameters in patients with multiple sclerosis","volume":"20","author":"Nazari","year":"2020","journal-title":"BMC Neurol"},{"key":"10.1016\/j.msard.2026.107199_bib0034","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1179\/1743132812Y.0000000082","article-title":"Multiple sclerosis and pain","volume":"34","author":"Nick","year":"2012","journal-title":"Neurol. Res."},{"key":"10.1016\/j.msard.2026.107199_bib0035","article-title":"Association of clinical epidemiological factors to polypharmacy among patients with multiple sclerosis: real-life data","volume":"46","author":"Oliveira","year":"2021","journal-title":"ABCS Heal. Sci."},{"key":"10.1016\/j.msard.2026.107199_bib0036","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12883-021-02347-w","article-title":"Clinical characteristics of middle-aged and older patients with MS treated with interferon beta-1b: post-hoc analysis of a 2-year, prospective, international, observational study","volume":"21","author":"Patti","year":"2021","journal-title":"BMC Neurol."},{"key":"10.1016\/j.msard.2026.107199_bib0037","article-title":"Health care utilization associated with polypharmacy In patients with multiple sclerosis","volume":"20","author":"Rojanasarot","year":"2017","journal-title":"Value Heal."},{"key":"10.1016\/j.msard.2026.107199_bib0038","article-title":"Use of healthcare services by patients with multiple sclerosis in France over 2010-2015: a nationwide population-based study using health administrative data","volume":"5","author":"Roux","year":"2019","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"10.1016\/j.msard.2026.107199_bib0039","doi-asserted-by":"crossref","DOI":"10.1177\/20503121231178047","article-title":"Multiple sclerosis and lower urinary tract symptoms: a survey of prevalence, characteristic and urological evaluations","volume":"11","author":"Sharifiaghdas","year":"2023","journal-title":"SAGE Open Med."},{"key":"10.1016\/j.msard.2026.107199_bib0033","unstructured":"Statistics Netherlands (CBS) (2023) New socioeconomic status scores for districts and neighbourhoods. Available at: https:\/\/www.cbs.nl\/en-gb\/our-services\/customised-services-microdata\/microdata-conducting-your-own-research\/cbs-odissei-microdata-meetings\/bijeenkomsten\/new-socioeconomic-status-scores-for-districts-and-neighbourhoods (Accessed: 9 December 2024)."},{"key":"10.1016\/j.msard.2026.107199_bib0040","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.11124\/JBISRIR-D-18-00023","article-title":"Effects of health literacy interventions on health-related outcomes in socioeconomically disadvantaged adults living in the community: a systematic review","volume":"18","author":"Stormacq","year":"2020","journal-title":"JBI Evid. Synth."},{"key":"10.1016\/j.msard.2026.107199_bib0041","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.jpsychores.2014.02.013","article-title":"Polypharmacy in multiple sclerosis: relationship with fatigue, perceived cognition, and objective cognitive performance","volume":"76","author":"Thelen","year":"2014","journal-title":"J. Psychosom. Res."},{"key":"10.1016\/j.msard.2026.107199_bib0042","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1046\/j.1365-2710.2001.00377.x","article-title":"Prescribing for multiple sclerosis patients in general practice: a case-control study","volume":"26","author":"Tremlett","year":"2001","journal-title":"J. Clin. Pharm. Ther."},{"key":"10.1016\/j.msard.2026.107199_bib0043","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.genhosppsych.2003.12.001","article-title":"Patients\u2019 preferences in the treatment of depressive disorder in primary care","volume":"26","author":"Van Schaik","year":"2004","journal-title":"Gen. Hosp. Psychiatry"},{"key":"10.1016\/j.msard.2026.107199_bib0044","doi-asserted-by":"crossref","DOI":"10.1093\/ije\/dyaf017","article-title":"Data resource profile: nivel primary care database (Nivel-PCD), the Netherlands","volume":"54","author":"Vanhommerig","year":"2025","journal-title":"Int. J. Epidemiol"},{"key":"10.1016\/j.msard.2026.107199_bib0045","unstructured":"Vektis (2024) Business intelligence centrum voor de zorg. Available at: https:\/\/www.vektis.nl\/ (Accessed: 18 January 2024)."},{"key":"10.1016\/j.msard.2026.107199_bib0046","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1177\/1352458520970841","article-title":"Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition","volume":"26","author":"Walton","year":"2020","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2026.107199_bib0047","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.msard.2017.12.006","article-title":"Treatment satisfaction and bothersome bladder, bowel, sexual symptoms in multiple sclerosis","volume":"20","author":"Wang","year":"2018","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2026.107199_bib0048","doi-asserted-by":"crossref","unstructured":"Wijnands, J.M.A., Kingwell, E., Zhu, F., Zhao, Y., Fisk, J.D., Evans, C., Marrie, R.A., Tremlett, H., 2016. Infection-related health care utilization among people with and without multiple sclerosis. 23, 1506\u20131516. https:\/\/doi.org\/10.1177\/1352458516681198.","DOI":"10.1177\/1352458516681198"},{"key":"10.1016\/j.msard.2026.107199_bib0001","unstructured":"World Health Organization (2019) Anatomical Therapeutic Chemical (ATC) Classification. Available at: https:\/\/www.who.int\/tools\/atc-ddd-toolkit\/atc-classification (Accessed: 20 February 2025)."},{"key":"10.1016\/j.msard.2026.107199_bib0049","doi-asserted-by":"crossref","DOI":"10.1177\/2040622320983121","article-title":"Exploring polypharmacy phenomenon in newly diagnosed relapsing\u2013remitting multiple sclerosis: a cohort ambispective single-centre study","volume":"12","author":"Zangh\u00ec","year":"2021","journal-title":"Ther. Adv. Chronic Dis."},{"key":"10.1016\/j.msard.2026.107199_bib0050","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00415-023-12041-1","article-title":"Multiple sclerosis in the elderly: a retrospective cohort study","volume":"271","author":"Zinganell","year":"2024","journal-title":"J. Neurol."}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600235X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103482600235X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T15:25:48Z","timestamp":1780327548000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103482600235X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":50,"alternative-id":["S221103482600235X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2026.107199","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prescriptions and healthcare use in multiple sclerosis patients within general practices in the Netherlands","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2026.107199","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107199"}}